Japan will apply price reductions for Novo Nordisk’s Wegovy (semaglutide), Novartis’ Leqvio (inclisiran), and Kyowa Kirin’s Phozevel (tenapanor) under the cost-effectiveness assessment (CEA) scheme, effective November 1. The Central Social Insurance Medical Council (Chuikyo) approved the new NHI prices for…
To read the full story
Related Article
REGULATORY
- Cabinet-Backed Health Insurance Bill Targets Childbirth Costs, Copay Reform
March 16, 2026
- Japan Cabinet Approves Health Insurance Bill with OTC-Like Drug Charges
March 16, 2026
- LDP Urges Action on Drug Supply Risks Linked to Reliance on Specific Countries
March 16, 2026
- 874 Defects or Health Damages Reported for Regenerative Medical Products in 1H FY2025
March 13, 2026
- Chuikyo OKs Listing of J&J’s Rybrofaz, Peak Sales Seen at 43.8 Billion Yen
March 12, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





